Agomab bags $114 million in thriving regenerative medicine sector
The Belgian company Agomab Therapeutics has topped up its Series B round by $40.5 million…
July 14, 2022 - 3 minutes
Argenx
Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease
US regulators have approved the first-in-class drug efgartigimod for the treatment of the rare muscle…
December 21, 2021 - 4 minutes
The Billion-Euro European Biotech Companies in 2022
Here’s a list of the public European biotech companies that are worth more than a…
December 20, 2021 - 12 minutes
Delayed IPOs and Market Drops Batter Biotech Stocks
Stock markets worldwide have experienced painful instability in the last few months. As a result,…
May 25, 2021 - 6 minutes
The 21 European Biotech Companies To Watch in 2021
As we enter 2021, the biotech industry is already bustling with activity. Here’s a list…
January 11, 2021 - 11 minutes
Argenx Follows up Phase III Success with Giant €785M Global Offering
The Dutch biotech argenx has cashed in on recent positive phase III results by launching…
May 29, 2020 - 2 minutes
Argenx’s Rare Disease Treatment Strikes Gold in Phase III
The Dutch biotech argenx aims to apply for FDA approval of its lead candidate efgartigimod…
May 26, 2020 - 3 minutes
Argenx Raises Whopping €502M in Global Offering
The Dutch biotech argenx, which develops antibody drugs to treat autoimmune diseases and cancer, has…
November 11, 2019 - 2 minutes
€21M Series A to Finance Belgian Biotech’s Regenerative Antibodies
The Belgian biotech AgomAb has raised €21M and partnered with the Dutch biotech argenx to…
April 3, 2019 - 2 minutes
Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal
Autoimmune disease and acute myeloid leukemia may have a llama-inspired antibody treatment one day. The…
December 5, 2018 - 3 minutes
Argenx Attracts Huge €250M Investment Following Positive Phase II Trial
Belgian biotech Argenx raised over €250M in public investment on the Nasdaq Stock Market after…
September 19, 2018 - 2 minutes
Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies
Argenx has smashed its target of $150M for its US offering, which will support its cancer…
December 14, 2017 - 1 minute
